BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 29105343)

  • 1. Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis.
    Ailawadhi S; Frank RD; Advani P; Swaika A; Temkit M; Menghani R; Sharma M; Meghji Z; Paulus S; Khera N; Hashmi SK; Paulus A; Kakar TS; Hodge DO; Colibaseanu DT; Vizzini MR; Roy V; Colon-Otero G; Chanan-Khan AA
    Cancer Med; 2017 Dec; 6(12):2876-2885. PubMed ID: 29105343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities.
    Ailawadhi S; Frank RD; Sharma M; Menghani R; Temkit M; Paulus S; Khera N; Hashmi S; Advani P; Swaika A; Paulus A; Aslam N; Sher T; Roy V; Colon-Otero G; Chanan-Khan A
    Cancer; 2018 Apr; 124(8):1710-1721. PubMed ID: 29360160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial disparities in treatment use for multiple myeloma.
    Fiala MA; Wildes TM
    Cancer; 2017 May; 123(9):1590-1596. PubMed ID: 28085188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.
    Olszewski AJ; Dusetzina SB; Eaton CB; Davidoff AJ; Trivedi AN
    J Clin Oncol; 2017 Oct; 35(29):3306-3314. PubMed ID: 28541791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival Trends in Young Patients With Multiple Myeloma: A Focus on Racial-Ethnic Minorities.
    Ailawadhi S; Azzouqa AG; Hodge D; Cochuyt J; Jani P; Ahmed S; Sher T; Roy V; Ailawadhi M; Alegria VR; Manochakian R; Vishnu P; Grover A; Abdulazeez MF; Paulus A; Chanan-Khan A
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):619-623. PubMed ID: 31377212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States.
    Warren JL; Harlan LC; Stevens J; Little RF; Abel GA
    J Clin Oncol; 2013 Jun; 31(16):1984-9. PubMed ID: 23569317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis.
    Ailawadhi S; Advani P; Yang D; Ghosh R; Swaika A; Roy V; Foran J; Colon-Otero G; Chanan-Khan A
    Cancer; 2016 Feb; 122(4):618-25. PubMed ID: 26565660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial and Ethnic Disparities in Utilization Rate, Hospital Volume, and Perioperative Outcomes After Total Knee Arthroplasty.
    Zhang W; Lyman S; Boutin-Foster C; Parks ML; Pan TJ; Lan A; Ma Y
    J Bone Joint Surg Am; 2016 Aug; 98(15):1243-52. PubMed ID: 27489314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial Disparities in the Utilization of Novel Agents for Frontline Treatment of Multiple Myeloma.
    Fiala MA; Wildes TM; Vij R
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):647-651. PubMed ID: 32522440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis.
    Ailawadhi S; Parikh K; Abouzaid S; Zhou Z; Tang W; Clancy Z; Cheung C; Zhou ZY; Xie J
    Blood Adv; 2019 Oct; 3(20):2986-2994. PubMed ID: 31648322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Racial/ethnic differences in survival among elderly patients with a primary glioblastoma.
    Barnholtz-Sloan JS; Maldonado JL; Williams VL; Curry WT; Rodkey EA; Barker FG; Sloan AE
    J Neurooncol; 2007 Nov; 85(2):171-80. PubMed ID: 17530174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
    Chari A; Parikh K; Ni Q; Abouzaid S
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disparities in Utilization of Autologous Stem Cell Transplantation as Consolidative Therapy for Multiple Myeloma: A Single Institution Retrospective Review.
    Lupak O; Xiaoxia H; Xie P; Thanikachalam K; Jabbour-Aida H; Farhan S; Emole J
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e680-e685. PubMed ID: 34148850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer.
    Schmid M; Meyer CP; Reznor G; Choueiri TK; Hanske J; Sammon JD; Abdollah F; Chun FK; Kibel AS; Tucker-Seeley RD; Kantoff PW; Lipsitz SR; Menon M; Nguyen PL; Trinh QD
    JAMA Oncol; 2016 Jan; 2(1):85-93. PubMed ID: 26502115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and therapy of multiple myeloma.
    Palumbo A; Cerrato C
    Korean J Intern Med; 2013 May; 28(3):263-73. PubMed ID: 23682217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries.
    Olszewski AJ; Dusetzina SB; Trivedi AN; Davidoff AJ
    J Clin Oncol; 2018 Oct; 36(28):2879-2886. PubMed ID: 30113885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [First-line treatment of multiple myeloma].
    Breitkreutz I; Raab M; Goldschmidt H
    Internist (Berl); 2019 Jan; 60(1):23-33. PubMed ID: 30552458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emerging role of novel therapies for the treatment of relapsed myeloma.
    Richardson PG; Hideshima T; Mitsiades C; Anderson KC
    J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.